Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIRNASDAQ:CTORNASDAQ:INZYNASDAQ:LFCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$3.10+4.4%$2.86$2.46▼$4.15$265.30M0.17312,510 shs546,463 shsCTORCitius Oncology$0.90-0.6%$0.79$0.55▼$4.42$64.04M-0.171.06 million shs13,302 shsINZYInozyme Pharma$3.98+0.1%$1.68$0.72▼$6.24$256.63M1.35865,089 shs1.72 million shsLFCRLifecore Biomedical$6.88+1.6%$6.52$3.68▼$7.99$254.55M0.65241,249 shs135,616 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals0.00%+2.76%0.00%+2.76%-18.80%CTORCitius Oncology0.00%0.00%-1.62%-12.50%+90,999,900.00%INZYInozyme Pharma0.00%-0.25%+143.83%+262.39%-18.05%LFCRLifecore Biomedical0.00%-1.64%-9.33%+15.56%+13.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVIRAtea Pharmaceuticals2.7723 of 5 stars3.32.00.00.03.02.51.3CTORCitius OncologyN/AN/AN/AN/AN/AN/AN/AN/AINZYInozyme Pharma3.3674 of 5 stars4.23.00.00.03.82.50.0LFCRLifecore Biomedical1.7525 of 5 stars2.32.00.00.01.94.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0093.55% UpsideCTORCitius Oncology 2.00Hold$3.00235.20% UpsideINZYInozyme Pharma 2.44Hold$11.75195.60% UpsideLFCRLifecore Biomedical 2.50Moderate Buy$8.0016.36% UpsideCurrent Analyst Ratings BreakdownLatest CTOR, INZY, LFCR, and AVIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CTORCitius OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/23/2025CTORCitius OncologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/21/2025LFCRLifecore BiomedicalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/16/2025INZYInozyme PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold5/16/2025INZYInozyme PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$4.005/16/2025INZYInozyme PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$15.00 ➝ $4.005/14/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.004/11/2025AVIRAtea PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.20 ➝ $6.004/10/2025INZYInozyme PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$6.65 per shareN/ACTORCitius OncologyN/AN/AN/AN/A($0.22) per shareN/AINZYInozyme PharmaN/AN/AN/AN/A$2.27 per shareN/ALFCRLifecore Biomedical$130.31M1.95N/AN/A$0.37 per share18.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$135.96M-$1.65N/AN/AN/AN/A-34.90%-32.38%8/6/2025 (Estimated)CTORCitius Oncology-$21.15MN/A0.00∞N/AN/A-43.67%-9.74%N/AINZYInozyme Pharma-$71.17M-$1.69N/AN/AN/AN/A-88.42%-57.02%8/5/2025 (Estimated)LFCRLifecore Biomedical$12.01M-$1.45N/AN/AN/A-12.52%-315.23%-12.74%8/15/2025 (Estimated)Latest CTOR, INZY, LFCR, and AVIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025CTORCitius Oncology-$0.09-$0.11-$0.02-$0.11$5.74 millionN/A5/14/2025Q1 2025INZYInozyme Pharma-$0.43-$0.44-$0.01-$0.44N/AN/A5/12/2025Q1 2025AVIRAtea Pharmaceuticals-$0.56-$0.40+$0.16-$0.40N/AN/A4/3/2025Q3 2025LFCRLifecore Biomedical-$0.14-$0.19-$0.05-$0.47$33.23 million$35.15 million3/6/2025Q4 2024AVIRAtea Pharmaceuticals-$0.35-$0.40-$0.05-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ACTORCitius OncologyN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A19.3319.33CTORCitius Oncology0.080.340.08INZYInozyme Pharma0.517.687.68LFCRLifecore Biomedical9.212.321.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%CTORCitius Oncology70.52%INZYInozyme Pharma88.30%LFCRLifecore Biomedical83.36%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals18.10%CTORCitius Oncology4.57%INZYInozyme Pharma12.18%LFCRLifecore Biomedical32.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7085.58 million69.43 millionOptionableCTORCitius OncologyN/A71.55 million55.17 millionN/AINZYInozyme Pharma5064.56 million57.05 millionOptionableLFCRLifecore Biomedical69037.03 million26.58 millionOptionableCTOR, INZY, LFCR, and AVIR HeadlinesRecent News About These CompaniesBronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Shareholders to Inquire about Securities InvestigationJune 1 at 10:00 AM | accessnewswire.comLifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Sold by BNP Paribas Financial MarketsJune 1 at 3:20 AM | marketbeat.comInsider Selling: Lifecore Biomedical, Inc. (NASDAQ:LFCR) Major Shareholder Sells 96,137 Shares of StockMay 30 at 10:53 PM | marketbeat.comAron R. English Sells 150,419 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) StockMay 30 at 10:51 PM | marketbeat.comLifecore Biomedical, Inc. (NASDAQ:LFCR) Major Shareholder Aron R. English Sells 1,139,504 SharesMay 30 at 10:48 PM | marketbeat.comLifecore Biomedical (NASDAQ:LFCR) shareholders have endured a 37% loss from investing in the stock five years agoMay 29, 2025 | finance.yahoo.comLifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationMay 29, 2025 | accessnewswire.comLifecore Biomedical, Inc. (NASDAQ:LFCR) Major Shareholder Aron R. English Sells 96,137 SharesMay 29, 2025 | insidertrades.comBronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to ConnectMay 27, 2025 | accessnewswire.comLifecore Biomedical Names Mark DaFonseca Chief Commercial OfficerMay 27, 2025 | globenewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities InvestigationMay 25, 2025 | accessnewswire.comQ4 Earnings Estimate for LFCR Issued By William BlairMay 25, 2025 | marketbeat.comLifecore Biomedical (NASDAQ:LFCR) Now Covered by Analysts at William BlairMay 24, 2025 | americanbankingnews.comWilliam Blair Initiates Coverage on Lifecore Biomedical (NASDAQ:LFCR)May 23, 2025 | marketbeat.comLifecore stock gains on Outperform rating by William BlairMay 22, 2025 | investing.comWhat Makes Lifecore Biomedical (LFCR) a Beneficiary of the Trade Policies?May 22, 2025 | msn.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Investors to Learn More About the InvestigationMay 22, 2025 | accessnewswire.comWilliam Blair Initiates Coverage of Lifecore Biomedical (LFCR) with Outperform RecommendationMay 22, 2025 | msn.comLifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationMay 20, 2025 | accessnewswire.comGreenhaven Road Capital Main Fund Q1 2025 Investor LetterMay 19, 2025 | seekingalpha.comLifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the InvestigationMay 18, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyTurbulence for Joby Shares: What's Behind the Recent Dip?By Jeffrey Neal Johnson | May 22, 2025View Turbulence for Joby Shares: What's Behind the Recent Dip?Google Is Betting Big on Nuclear Reactors—Should You?By Dan Schmidt | May 9, 2025View Google Is Betting Big on Nuclear Reactors—Should You?3 Mid-Cap Stocks Turning Heads in AI, Automation, & CybersecurityBy Nathan Reiff | May 16, 2025View 3 Mid-Cap Stocks Turning Heads in AI, Automation, & CybersecurityCTOR, INZY, LFCR, and AVIR Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$3.10 +0.13 (+4.38%) Closing price 04:00 PM EasternExtended Trading$3.10 0.00 (-0.16%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Citius Oncology NASDAQ:CTOR$0.90 -0.01 (-0.56%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Inozyme Pharma NASDAQ:INZY$3.98 +0.01 (+0.13%) Closing price 03:59 PM EasternExtended Trading$3.98 +0.00 (+0.13%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Lifecore Biomedical NASDAQ:LFCR$6.88 +0.11 (+1.55%) Closing price 03:59 PM EasternExtended Trading$6.86 -0.01 (-0.15%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
